CG Oncology Inc. Common s... (CGON)

NASDAQ: CGON · Real-Time Price · USD

27.76

0.82 (3.04%)

At close: May 01, 2025, 3:59 PM

28.20

1.59%

After-hours: May 01, 2025, 04:04 PM EDT

3.04% (1D)

Bid	27.04
Market Cap	2.12B
Revenue (ttm)	1.14M
Net Income (ttm)	-88.04M
EPS (ttm)	-1.41
PE Ratio (ttm)	-19.69
Forward PE	-17.29
Analyst	Buy

Ask	29.36
Volume	716,174
Avg. Volume (20D)	1,074,908
Open	27.00
Previous Close	26.94
Day's Range	26.24 - 27.88
52-Week Range	14.80 - 46.99
Beta	1.24

About CGON

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date n/a

Employees 113

Stock Exchange NASDAQ

Ticker Symbol CGON

Full Company Profile

Analyst Forecast

According to 9 analyst ratings, the average rating for CGON stock is "Buy." The 12-month stock price forecast is $65, which is an increase of 134.15% from the latest price.

Stock Forecasts

Next Earnings Release

CG Oncology Inc. Common stock is scheduled to release its earnings on May 12, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 days ago

+25.03%

CG Oncology shares are trading higher after the co... Unlock content with Pro Subscription

3 months ago

+4.34%

CG Oncology shares are trading higher after TD Cowen initiated coverage on the stock with a Buy rating.

News

9 hours ago · zacks.com

CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

CG Oncology, Inc. (CGON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 day ago · zacks.com

CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains?

CG Oncology, Inc. (CGON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near...

3 days ago · benzinga.com

CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why

75.5% complete response rate reported in BOND-003 Cohort C study for high-risk NMIBC patients unresponsive to BCG.

4 weeks ago · seekingalpha.com

CG Oncology Looks Attractive At Current Prices (Rating Upgrade)

CG Oncology, Inc.'s lead asset, cretostimogene grenadenorepvec, shows promising efficacy in bladder cancer with competitive complete response rates in clinical trials. Recent data updates reveal a 74....

1 month ago · zacks.com

Wall Street Analysts Believe CG Oncology, Inc. (CGON) Could Rally 157.91%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 157.9% in CG Oncology, Inc. (CGON). While the effectiveness of this highly sought-after metric is questionable,...